DefiniumDFTX
NASDAQMedicinal Chemicals
No cached AI snapshot yet for DFTX.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
106 employees99.70M shares outstandinglisted 2020-03-03
About Definium
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
Latest News
Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 ODT in Generalized Anxiety Disorder Transcript
Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 ODT in Generalized Anxiety Disorder - Slideshow
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
Treasury ETF shorts shift toward belly ahead of Fed decision
BoE to 'stand ready to hike', committee remains 'deeply divided'
The Fed’s interest rate decision in the epicenter of attention
Related Stocksin Medicinal Chemicals
Ready to see the live AI view on DFTX?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing DFTX side-by-side with live signals.